leadf
logo-loader
viewMaxCyte Inc

MaxCyte commercial arm trading ahead of expectations; working on strategy for and future funding of the CARMA business

A more comprehensive assessment of MaxCyte’s financial performance will be given next month

MaxCyte Inc -

MaxCyte Inc (LON:MXCT) has said it expects financial results for its core life sciences business to be ahead of schedule, citing momentum in “transformational cell therapies” and milestone payments from licence partnerships.

In the same update, the group said it continues to work with the life sciences transactions specialist Locust Walk on a strategy for and future funding of the group's CARMA business.

This subsidiary is developing immuno-oncology drugs using MaxCyte’s cell engineering technology and is aiming to become self-funding.

The company said enrolment and dosing in the existing CARMA no-preconditioning clinical study of MCY-M11, an early-stage drug candidate designed to treat ovarian cancer, is “continuing well”.

MaxCyte added that it has always operated a twin-strand approach. So, as well as being a drug developer it also licences out its know-how and kit to some of the world’s largest pharma and biotech companies.

A more comprehensive assessment of MaxCyte’s financial performance will be given on January 18, 2021, the group said.

Quick facts: MaxCyte Inc

Price: 860 GBX

AIM:MXCT
Market: AIM
Market Cap: £815.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte report 'extraordinary first half' with revenue 30% higher than same...

Maxcyte Inc's (LON:MXCT) Doug Doerfler talks to Proactive London about their full-year revenues which are on track to be 'slightly above' current market expectations. Doerfler discusses what he describes as an 'extraordinary first half' with half year revenue 30% higher than the same period...

on 1/10/20

2 min read